Evidence map›Paper›PMID 37222770›Full record

ArticleCancer immunology, immunotherapy : CII2023

Enhanced HPV16 E6/E7

Toon Stegmann, Anna-Sophia Wiekmeijer, Kitty Kwappenberg, Suzanne van Duikeren, Farien Bhoelan, Denzel Bemelman, Thomas J M Beenakker, Willem-Jan Krebber, Ramon Arens, Cornelis J M Melief

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Virosomes: Beyond Vaccines.Life (Basel, Switzerland) · 2025
    Review
  3. Review
  4. Review
  5. Development of semisynthetic saponin immunostimulants.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Toon Stegmann *Mymetics BV, J.H, Oortweg 21, 2333 CH, Leiden, The Netherlands. toon.stegmann@mymetics.com.
Anna-Sophia Wiekmeijer *ISA Pharmaceuticals BV, De Limes 7, 2342 DH, Oegstgeest, The Netherlands.
Kitty KwappenbergISA Pharmaceuticals BV, De Limes 7, 2342 DH, Oegstgeest, The Netherlands.
Suzanne van DuikerenImmunology department, Leiden Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Farien BhoelanMymetics BV, J.H, Oortweg 21, 2333 CH, Leiden, The Netherlands.
Denzel BemelmanMymetics BV, J.H, Oortweg 21, 2333 CH, Leiden, The Netherlands.
Thomas J M BeenakkerISA Pharmaceuticals BV, De Limes 7, 2342 DH, Oegstgeest, The Netherlands.
Willem-Jan KrebberISA Pharmaceuticals BV, De Limes 7, 2342 DH, Oegstgeest, The Netherlands.
Ramon ArensImmunology department, Leiden Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Cornelis J M MeliefISA Pharmaceuticals BV, De Limes 7, 2342 DH, Oegstgeest, The Netherlands.
ISA Pharmaceuticals (Netherlands) · NLLeiden University Medical Center · NLMimetas (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic cancer vaccines trigger CD4 + and CD8 + T cell responses capable of established tumor eradication. Current platforms include DNA, mRNA and synthetic long peptide (SLP) vaccines, all aiming at robust T cell responses. SLPs linked to the Amplivant® adjuvant (Amplivant-SLP) have shown effective delivery to dendritic cells, resulting in improved immunogenicity in mice. We have now tested virosomes as a delivery vehicle for SLPs. Virosomes are nanoparticles made from influenza virus membranes and have been used as vaccines for a variety of antigens. Amplivant-SLP virosomes induced the expansion of more antigen-specific CD8 + T memory cells in ex vivo experiments with human PBMCs than Amplivant-SLP conjugates alone. The immune response could be further improved by including the adjuvants QS-21 and 3D-PHAD in the virosomal membrane. In these experiments, the SLPs were anchored in the membrane through the hydrophobic Amplivant adjuvant. In a therapeutic mouse model of HPV16 E6/E7

Indexed as

Cancer VaccinesNeoplasmsAdjuvants, ImmunologicAnimalsCD8-Positive T-LymphocytesHuman papillomavirus 16HumansMiceMice, Inbred C57BLPapillomavirus E7 ProteinsPeptidesVaccinationVaccines, SyntheticVirosomesAdjuvants, ImmunologicCancer VaccinesPapillomavirus E7 ProteinsPeptidesVaccines, SyntheticVirosomesCancer immunotherapyCancer vaccinesCervical cancerHuman Papilloma virus

Identifiers

PMID37222770
PMCPMC10361876
OpenAlexW4377940892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.